Jagsonpal Pharmaceuticals Gears Up for Q3 Reveal on 21st January; Check Key Expectations Here

Tue Jan 20 2026

Click and Sign Up to Get Live Updates on Q3 Results

Jagsonpal Pharmaceuticals, one of the most significant Indian conglomerates, is set to announce its Q3 FY26 results on 21st January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Jagsonpal Pharmaceuticals Q3 Results 2026 Preview

Jagsonpal Pharmaceuticals’ revenue is expected to be in the range of ₹74.03 crore, a 0.89% YoY decrease.
Profit After Tax, or PAT, is projected to rise by 179.17% YoY.
Jagsonpal Pharmaceuticals’ EBITDA is expected to rise to ₹36.61 crore.
Net profit is ₹74.03 crore, a down by 0.89% YoY

Jagsonpal Pharmaceuticals Share Performance

Over the past six months, Jagsonpal Pharmaceuticals’s share price has fallen by 30.94% to ₹171.99.
Moreover, over the past year, the stock has decreased by 25.64%.
Despite this weak short-term performance, Jagsonpal Pharmaceuticals’s stock has delivered a financially sound 474.45% return over the past 5 years.
As of 20th January 2026, the stock traded at ₹171.99 per share.

Key Factors to Watch for Jagsonpal Pharmaceuticals

Brand Strength & Market Position: Growth and market share of key brands (such as Indocap) across therapeutic segments, including gynaecology, pain management, and dermatology, which drive revenue and pricing power.
Revenue & Margin Expansion: Sustained revenue growth and improvement in EBITDA/PAT margins through disciplined execution, cost control, and product mix optimisation.
Product Pipeline & New Launches: Introduction of new formulations and portfolio expansion to address unmet demand and capture higher market share.
Balance Sheet & Cash Generation: Strong free cash flow, working capital efficiency, and strategic use of cash for organic/inorganic growth opportunities such as acquisitions or capacity expansion.

Final Thoughts

Jagsonpal Pharmaceuticals will announce its Q3 FY26 results on 21st January 2026. Analysts expect 0.89% YoY revenue growth, a 179.17% rise in PAT, and a 162.51% rise in EBITDA. Jagsonpal Pharmaceuticals focuses on building strong branded formulations through new product launches, therapeutic diversification, and efficient cost management to drive sustainable growth.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!